Amgen is partnering with the Australian Cancer Research Foundation with three initiatives to support women in cancer research following a survey that found 57 per cent of women in the sector reported facing gender discrimination.
Australian Cancer Research Foundation (ACRF) and Amgen’s 'Empowering Women in Cancer Research' surveyed female researchers across Australia. The survey found that women in cancer research face significant obstacles, from gender discrimination, ageism and an absence of mentorship to a lack of funding and job security, all of which are pushing them out of the industry.
According to the national survey, 90 per cent of respondents identified greater funding for cancer research, specifically for women, as a key need. Three-quarters (75 per cent) identified the need for supportive mentors, and 68 per cent identified flexible work options as critical enablers for retention. Respondents agreed that maternity leave and lack of job security are driving women out mid-career. Work-life balance also remains elusive, and while 65 per cent aim for senior roles, only 58 per cent see themselves working in the sector in 10 years.
As a result of the study, ACRF and Amgen have partnered to launch three initiatives, including a three-year $100,000 per annum grant specifically for women in cancer research who are part of an ACRF-funded project. They are also launching five preceptorships for female cancer researchers involved in ACRF grant-funded projects, hosted by Amgen, which include travel to their US facilities. Additionally, an industry-specific webinar series is being designed to tackle these issues and provide positive role models, guidance, and support for women to further their careers in cancer research.
"This study paints a clear picture: many of the incredible women dedicated to finding better options for treatment, detection and prevention of cancer are facing uphill battles that hinder their progress and even force them out of the field," said ACRF CEO Kerry Strydom.
"We are losing brilliant scientists because of systemic issues that need fixing. This may impact not just individual careers, but the very pace and advancement of cancer research in Australia."
Cae Tolman, country senior medical director for Amgen Australia and New Zealand, said, "This isn’t just a women’s issue, it’s an industry issue. If we’re serious about finding the next cancer breakthrough, we need all our talent at the table.
“When we empower women in science, we empower science itself. Every woman who leaves cancer research is a potential breakthrough lost. We must ensure they have the support and opportunities they need to continue their vital work," said Tolman.
The 'Empowering Women in Cancer Research' invited female cancer researchers to participate in the survey anonymously. One researcher shared that she avoids telling people she has a child, fearing she will not be taken seriously. Another revealed that, since returning from maternity leave, she must work twice as hard as her male counterparts to prove her commitment.
“We hope that this study and the other campaign initiatives help to empower women in research to improve representation, leadership, funding and development,” continued Strydom.
“While we know this isn’t going to immediately solve the concerns of our female researchers, Amgen and ACRF are pleased to pioneer this initiative as a starting point and are proud of the part we can play to begin to change the narrative for women in the sector,” added Tolman.